Literature DB >> 12383692

Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.

Fabio Mosca, Milena Bray, Ilaria Stucchi, Monica Fumagalli.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383692     DOI: 10.1016/S0140-6736(02)11109-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Effects of combined hyperoxia and cyclooxygenase inhibition in neonatal rat lungs.

Authors:  Katherine M Kuniyoshi; Romy S Brock; Bisrat H Gebrekristos; Matthew Abad-Santos; Dinh Hoang; Houchang D Modanlou; Brigham C Willis; Kay D Beharry
Journal:  Am J Transl Res       Date:  2010-06-08       Impact factor: 4.060

2.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2019-06-21

3.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-01-27

4.  Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.

Authors:  Karen E Corff; Kris C Sekar
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

Review 5.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 6.  Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?

Authors:  Vassilios Fanos; Michele Pusceddu; Angelica Dessì; Maria Antonietta Marcialis
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 7.  Patent ductus arteriosus in preterm infants: do we have the right answers?

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.